Tirzepatide vs. Retatrutide: Which One Actually Costs More?

How the dosing protocols actually work

Both compounds use a slow titration approach: you start low and increase the dose incrementally over weeks to months. This reduces side effects and lets the body adjust. But the dose ceilings are very different.

Tirzepatide follows the protocol established in its clinical trials (the SURMOUNT and SURPASS series): starting at 2.5 mg per week, increasing by 2.5 mg every four weeks as tolerated. The maximum studied dose is 15 mg per week. In practice, most research protocols settle somewhere between 5 and 10 mg per week for maintenance. That means a single week of tirzepatide at a moderate maintenance dose uses 7.5 to 10 mg of the compound.

Retatrutide was studied at significantly lower doses in Phase 2 trials. Starting doses in the trial were 0.5 to 1 mg per week, titrating up to 2, 4, and 8 mg over several months. The highest dose arm used 12 mg per week, but the 4 and 8 mg groups showed substantial weight loss with a more manageable side effect profile. For context: the 8 mg group in the main Phase 2 trial showed mean weight loss exceeding 17% at 24 weeks, and around 24% at 48 weeks. A weekly maintenance dose of 4 to 8 mg captures most of what the research documented.

The practical upshot: a week of tirzepatide at maintenance doses uses roughly two to three times more milligrams than a week of retatrutide at comparable research doses.

The weekly cost comparison

Using current median vendor pricing (approximately $9/mg for tirzepatide and $50/mg for retatrutide across research suppliers), here is what a week of each compound actually costs:

The dosing gap is real and it matters. Retatrutide is not five times more expensive per week. It's closer to three to four times more expensive at equivalent protocol stages. That's still a significant difference, and it doesn't close. But it's a more honest number to work from than the raw per-milligram comparison suggests.

Vendor pricing also varies substantially. The low end of the retatrutide market runs around $20/mg; the low end for tirzepatide is closer to $4/mg. At those prices, the weekly cost gap narrows further, but the relative difference holds.

Why retatrutide uses lower doses at all

The dose difference isn't arbitrary or a marketing quirk. It reflects a genuine difference in potency and mechanism.

Tirzepatide activates two receptors: GLP-1 and GIP. Both contribute to appetite suppression and improved insulin response. The compound needs to be present in sufficient quantity to drive meaningful activation of both pathways, which is why doses climb into the 5–15 mg range.

Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The glucagon receptor component adds a metabolic dimension that the dual agonists don't have: it increases energy expenditure, not just appetite suppression. That third pathway appears to amplify the overall effect, which is part of why the compound produces outsized weight loss results at relatively modest doses. You're not just suppressing appetite more; you're also turning up the metabolic rate in a way that tirzepatide doesn't directly accomplish.

For women in perimenopause or post-menopause, that metabolic dimension is worth understanding specifically. Metabolic rate tends to slow with the hormonal changes of midlife, not because of caloric intake or exercise habits, but as a direct physiological effect. A compound that addresses energy expenditure alongside appetite is mechanistically relevant to that picture in a way that a GLP-1 or dual agonist isn't. That doesn't mean it's the right choice for everyone, but it's why some researchers and clinicians are paying close attention to the triple agonist approach for this population.

What you're actually paying for

If tirzepatide runs you roughly $90/week at a 10 mg maintenance dose, and retatrutide runs you roughly $200/week at a 4 mg maintenance dose, the question becomes whether the additional cost maps to additional benefit.

Based on the available trial data: tirzepatide produced average weight loss of around 20–22% of body weight in its Phase 3 trials. Retatrutide's Phase 2 data showed 24% or more at 48 weeks. Those aren't comparable trials run under identical conditions, so direct comparison has limits. But the directional signal (that retatrutide may outperform tirzepatide on total weight outcomes) is consistent across the data published so far.

What isn't yet settled is the full side effect profile, the long-term safety picture, and how retatrutide performs in Phase 3 trials with larger, more diverse populations. Tirzepatide has years of post-approval real-world data. Retatrutide does not. That's not a reason to dismiss it, but it's a meaningful difference in the confidence level the evidence supports.

The premium for retatrutide isn't irrational if the outcomes match the early data. It is worth understanding clearly before assuming the per-milligram price makes it unaffordable, because the per-dose math is considerably less stark than the per-milligram number implies.

A note on approval status

Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). A prescription path exists. Retatrutide is in Phase 3 clinical trials as of mid-2026 and does not have FDA approval. Both are available in research markets, but the regulatory situation is different, and that affects how each compound can be accessed and used.

For the full research notes on each compound, including mechanism detail, trial citations, and current vendor pricing, see the Tirzepatide research note and the Retatrutide research note. To compare current prices across vendors, use the Peptide Price Lab pricing tool.

Citations for the clinical trial data referenced here are listed in the Tirzepatide and Retatrutide research notes. To compare current prices across vendors, see the Vendor Directory. For more on GLP-1 compounds and weight research, see the Weight Research and Metabolic Health tag pages.